Investment Rating - The report assigns a "Buy" rating for MINIMAX-WP (00100.HK) as a first-time recommendation [1]. Core Insights - MINIMAX has launched M2.5, the world's first production-grade model designed natively for agent scenarios, which is expected to redefine programming agents [8]. - The revenue forecast for MINIMAX is projected to grow significantly, with total revenue expected to reach $69.88 million in 2025, $194.04 million in 2026, and $398.10 million in 2027, reflecting year-on-year growth rates of 128.94%, 177.68%, and 105.16% respectively [1]. - The company is expected to experience a substantial increase in token usage, with M2.5 achieving a token call volume of 3.07 trillion within the first week of its launch, indicating strong market demand [8]. Financial Projections - The total revenue for MINIMAX is forecasted as follows: - 2023: $3.46 million - 2024: $30.52 million - 2025: $69.88 million - 2026: $194.04 million - 2027: $398.10 million [1]. - The net profit attributable to the parent company is projected to be negative, with estimates of $(269.25) million in 2023, $(465.24) million in 2024, and $(616.52) million in 2025, before improving to $(428.28) million in 2026 and $(476.52) million in 2027 [1]. - The EPS (Earnings Per Share) is expected to be $(0.86) in 2023, $(1.48) in 2024, $(1.97) in 2025, $(1.37) in 2026, and $(1.52) in 2027 [1]. Market Data - The closing price of MINIMAX is reported at HKD 763.50, with a market capitalization of approximately HKD 177,538.77 million [5]. - The company has a price-to-earnings (P/E) ratio of (117.55) for the current price and latest diluted earnings [1].

Investment Rating - The investment rating for the company is "Outperform the Market" [6][34]. Core Insights - The company achieved a revenue of HKD 29.161 billion in 2025, representing a year-on-year growth of 30.3%, and a net profit of HKD 17.754 billion, with a growth of 36.0% [1][8]. - The significant growth is driven by the increased trading activity in the Hong Kong stock market, with an average daily turnover (ADT) of HKD 2.315 trillion, a substantial increase of 92.9% year-on-year [1][13]. - The company's EBITDA margin reached a historical high of 78.2%, and the annualized return on equity (ROE) rose to 31.7%, surpassing the previous peak in 2015, highlighting the strong scale effects and high profitability of its asset-light operating model [1][8]. Revenue Structure - The main sources of revenue are trading fees and transaction system usage fees, along with settlement and clearing fees, which together accounted for 73.2% of total revenue in 2025 [2][8]. - The southbound capital flow has been a major driver of the increase in average daily turnover, with the southbound trading average reaching HKD 1.211 trillion, representing 26.2% of the total [2][13]. Market Context - The Hong Kong stock market is expected to continue attracting incremental capital, with both challenges and opportunities for technology stocks [2][21]. - Despite a slowdown in initial public offerings since 2021, many high-quality A-share companies have been listed in Hong Kong since 2024, injecting new vitality into the market [2][19]. Strategic Initiatives - The company is focused on deepening connectivity, enhancing market vitality, exploring innovative businesses, and strengthening technological empowerment [3][24]. - Key initiatives include optimizing and expanding the scope of the Stock Connect program, attracting quality assets through listing rule reforms, and developing non-traditional businesses such as data connectivity [3][25]. Financial Forecasts - The company is projected to achieve revenues of HKD 31.886 billion and HKD 34.302 billion in 2026 and 2027, respectively, with net profits expected to reach HKD 19.984 billion and HKD 21.428 billion [4][24]. - The EBITDA margin is expected to remain above 70%, reflecting the high gross margin characteristics of the asset-light model [24].

Investment Rating - The report assigns a positive investment rating, indicating a "Best-in-Class" potential for the company's product DB1311/BNT324 (B7H3 ADC) in treating late-line castration-resistant prostate cancer (CRPC) [3][9]. Core Insights - The latest efficacy and safety data for DB1311/BNT324 was presented at the 2026 ASCO Genitourinary Cancers Symposium, showcasing promising results in a Phase I/II clinical trial involving 104 patients [1][6]. - The median follow-up time was 9.2 months, with significant response rates: PSA50 response rate at 35.4%, confirmed overall response rate (ORR) at 34.5%, and disease control rate (DCR) at 87.9% [2][7]. - The median radiographic progression-free survival (rPFS) was reported at 11.3 months, with 6-month and 9-month rPFS rates of 72% and 63%, respectively [2][7]. - The safety profile was consistent with previous reports, primarily consisting of Grade 1-2 adverse events [2][7]. Summary by Sections Clinical Data - The clinical trial data included 104 patients, with 68 receiving 6 mg/kg Q3W treatment and 34 receiving 9 mg/kg Q3W treatment, and 53% of the patients were White [1][6]. - Among 82 evaluable patients, the median duration of response (DOR) was 10.2 months, indicating a strong survival benefit [2][7]. Comparative Analysis - The rPFS rate of 72% compares favorably against other treatments, such as Novartis' Lu177 and Johnson & Johnson's KLK2*CD3 TCE, which reported lower rPFS rates [3][9]. - The report highlights the potential of DB1311 to outperform existing therapies in terms of survival data, suggesting a strong competitive position in the market [3][9].

Investment Rating - The report maintains a "Buy" rating for Hong Kong Exchanges and Clearing Limited (0388) with a target price raised to HKD 502, corresponding to a 35x PE for 2025 [1][9]. Core Insights - The report highlights that the Hong Kong stock exchange benefited from high trading activity and an increase in margin investment, which offset the decline in yield, leading to better-than-expected profits in the fourth quarter [2][9]. - The continuous expansion of the Hong Kong stock market and the broadening of its service boundaries are expected to sustain the long-term profitability of the exchange [2][9]. - The report projects total revenue and net profit for 2025 to be HKD 291.6 billion and HKD 177.5 billion, respectively, representing year-on-year growth of 30% and 36% [9]. Financial Summary - Total revenue for 2024A is projected at HKD 22,374 million, increasing to HKD 29,161 million in 2025A, with a growth rate of 30.3% [4][10]. - Net profit is expected to rise from HKD 13,050 million in 2024A to HKD 17,754 million in 2025A, reflecting a growth rate of 36.0% [4][10]. - The report provides a breakdown of revenue sources for 2025, with significant contributions from spot trading (HKD 147 million, +56% YoY) and equity derivatives (HKD 69 million, +11% YoY) [9][10]. Market Data - The current stock price is HKD 415.40, with a market capitalization of HKD 526,659 million and a 52-week price range of HKD 297.00 to HKD 462.80 [6][9]. - The report indicates that the stock's price-to-earnings (PE) ratio is projected to decrease from 40.4 in 2024A to 29.66 in 2025A, indicating improved valuation [4][10]. Growth Drivers - The report emphasizes that the growth of the Hong Kong stock exchange is closely tied to the expansion of the Hong Kong stock market and the increasing demand for IPOs, particularly from mainland companies seeking internationalization [9][10]. - The anticipated improvement in overseas liquidity and domestic economic stabilization policies are expected to maintain high levels of investment activity in the Hong Kong stock market [9].

Investment Rating - The report does not explicitly state an investment rating for Duality Biologics (9606 HK) Core Insights - At the 2026 ASCO Genitourinary Cancers Symposium, Duality Biologics presented promising efficacy and safety data for its drug DB1311/BNT324 (B7H3 ADC) in treating late-line castration-resistant prostate cancer (CRPC) [1][6] - The data from the Phase I/II clinical trial included 104 treated patients, with a median of 4 prior lines of therapy [1][6] - As of September 5, 2025, the median follow-up was 9.2 months, with 52 patients still on treatment [2][7] - Among 58 evaluable patients, the PSA50 response rate was 35.4%, with a confirmed overall response rate (ORR) of 34.5% and a disease control rate (DCR) of 87.9% [2][7] - The median duration of response (DOR) was 10.2 months, and the median radiographic progression-free survival (rPFS) was 11.3 months [2][7] - The safety profile was consistent with previous reports, primarily consisting of Grade 1-2 adverse events [2][7] Summary by Sections Efficacy Data - The report highlights that the rPFS rate improved from 61% to 72% with an expanded sample size and extended follow-up [3][9] - The efficacy in patients who had previously received Lu177 treatment was also notable, with a PSA50 response rate of 30.4% and a DCR of 100% [8] Comparative Analysis - The rPFS rate of DB1311 compares favorably against other treatments, such as Novartis' Lu177 and Johnson & Johnson's KLK2*CD3 TCE, indicating its potential as a best-in-class therapy [3][9]

Investment Rating - The investment rating for the company is "Outperform the Market" [6][24]. Core Views - The company is expected to achieve significant revenue growth driven by the active trading environment in the Hong Kong market, with projected revenue of HKD 29.16 billion in 2025, representing a year-on-year increase of 30.3% [1][8]. - The net profit attributable to shareholders is forecasted to reach HKD 17.75 billion in 2025, reflecting a 36.0% year-on-year growth, supported by a substantial increase in daily trading volume [1][8]. - The company's EBITDA margin has reached a historical high of 78.2%, and the annualized return on equity (ROE) is projected to be 31.7%, indicating strong operational efficiency and profitability [1][8]. Revenue and Profit Structure - The primary sources of revenue are trading fees and transaction system usage fees, which together accounted for 73.2% of total revenue in 2025 [2][8]. - The average daily turnover (ADT) in the cash market is expected to be HKD 2.315 trillion in 2025, a significant increase of 92.9% year-on-year, driven mainly by southbound capital inflows [2][13]. - Southbound trading accounted for 26.2% of the overall daily turnover in the Hong Kong stock market, highlighting its importance in driving market activity [2][13]. Strategic Initiatives - The company is focusing on deepening connectivity with mainland markets, optimizing and expanding the scope of the Stock Connect program, and exploring innovative business opportunities such as data connectivity [3][24]. - Efforts to enhance market vitality include reforms in listing rules to attract high-quality assets and diverse investors [3][24]. - The company is also investing in technology to upgrade trading and settlement platforms, which will support future business expansion [3][24]. Financial Forecasts - Revenue is projected to grow from HKD 22.37 billion in 2024 to HKD 37.60 billion by 2028, with a compound annual growth rate (CAGR) of approximately 9.6% [4][32]. - Net profit is expected to increase from HKD 13.05 billion in 2024 to HKD 23.44 billion by 2028, reflecting a strong growth trajectory [4][32]. - The company’s PE ratio is forecasted to decrease from 40.4 in 2024 to 22.5 by 2028, indicating an improving valuation as earnings grow [4][32].

Investment Rating - The report maintains a "Buy" rating for Hong Kong Exchanges and Clearing Limited (HKEX) with a target price raised to HKD 502, corresponding to a 35x PE for 2025 [1][9]. Core Insights - The report highlights that HKEX's profits exceeded expectations in Q4 2025 due to sustained high trading activity in the Hong Kong stock market and growth in margin investment, which offset the decline in yield [2][9]. - The report anticipates continued growth in HKEX's long-term profitability driven by the expansion of the Hong Kong stock market and the broadening of its service boundaries, with ongoing IPO activity expected to enhance its revenue base [2][9]. Financial Summary - Total revenue for 2025 is projected at HKD 29,161 million, representing a year-on-year increase of 30.3%, while net profit is expected to reach HKD 17,754 million, up 36% from the previous year [4][10]. - The report provides a detailed breakdown of revenue sources for 2025, with significant contributions from spot trading (HKD 14.7 billion, +56% YoY), equity derivatives (HKD 6.9 billion, +11% YoY), and other segments [9][10]. - Investment income for 2025 is forecasted to be HKD 5.1 billion, reflecting a 4% increase YoY, driven by higher margin requirements and improved fund investment returns [9][10]. Growth Projections - The report projects net profits for 2026, 2027, and 2028 to be HKD 18.8 billion, HKD 19.7 billion, and HKD 20.7 billion, respectively, with growth rates of 6%, 5%, and 5% [9][10]. - The report emphasizes that HKEX's business model allows for long-term growth in line with the expansion of the Hong Kong stock market, which has historically maintained a revenue-to-market capitalization ratio of approximately 1.2% [9][10].

Investment Rating - The investment rating for the company is "Outperform the Market" [6][34]. Core Insights - The company achieved a revenue of HKD 29.161 billion in 2025, representing a year-on-year growth of 30.3%, and a net profit of HKD 17.754 billion, up 36.0% year-on-year, driven by increased trading activity in the Hong Kong stock market [1][8]. - The average daily trading volume (ADT) in the cash market reached HKD 231.5 billion in 2025, a significant increase of 92.9% year-on-year, highlighting the strong market demand [1][13]. - The company's EBITDA margin reached a historical high of 78.2%, and the annualized return on equity (ROE) rose to 31.7%, surpassing the previous peak in 2015, indicating robust operational efficiency and profitability [1][8]. Revenue Structure - The primary sources of revenue for the company in 2025 were trading fees and transaction system usage fees, which together accounted for 73.2% of total revenue, closely linked to market trading volumes [2][8]. - The southbound trading (Hong Kong Stock Connect) accounted for an average daily trading volume of HKD 121.1 billion, representing 26.2% of the overall daily trading volume in the Hong Kong stock market [2][13]. Market Context - The Hong Kong stock market is expected to continue attracting incremental capital, with a mix of challenges and opportunities for technology stocks [2][21]. - Despite a slowdown in initial public offerings (IPOs) since 2021, high-quality A-share companies have been listing in Hong Kong, injecting new vitality into the market [2][19]. Strategic Initiatives - The company is focusing on deepening connectivity, enhancing market vitality, exploring innovative businesses, and strengthening technological capabilities to maintain its competitive edge [3][24]. - Key initiatives include expanding the scope of the Stock Connect program and optimizing listing rules to attract quality assets and diverse investors [3][25]. Financial Projections - The company is projected to achieve revenues of HKD 31.886 billion and HKD 34.302 billion in 2026 and 2027, respectively, with net profits expected to reach HKD 19.984 billion and HKD 21.428 billion [4][24]. - The EBITDA margin is expected to remain above 70%, reflecting the company's high gross margin characteristics [24][28].

Investment Rating - The report maintains a "Buy" rating for Hong Kong Exchanges and Clearing Limited (00388.HK) [1] Core Views - The company's performance slightly exceeded expectations, with record trading volumes across multiple markets [1] - In 2025, Hong Kong Exchanges achieved revenue of HKD 29.161 billion, a year-on-year increase of 30%, and a net profit attributable to shareholders of HKD 17.754 billion, up 36% year-on-year [1] - The report anticipates continued growth in net profit for 2026-2028, projecting HKD 20.155 billion, HKD 21.786 billion, and HKD 23.707 billion respectively, with corresponding EPS of HKD 15.91, HKD 17.17, and HKD 18.64 [4] Revenue Analysis - Trading fees in the cash market saw a significant increase, with average daily turnover reaching HKD 231.5 billion, a 93% year-on-year growth, and trading fee income rising by 87% [2] - The derivatives market reported a revenue increase of 11%, driven by a 55% rise in average daily turnover for structured products [2] - The LME (London Metal Exchange) achieved its best performance in history, with trading fees and settlement fees increasing by 11% and 12% respectively [2] Listing Fees - The primary market in Hong Kong was very active in 2025, with 119 new listings, an increase of 48 from the previous year, and a fundraising amount that grew by 226% [3] - Listing fee income in the derivatives market increased by 38%, attributed to a 50% and 27% rise in new listings of structured products and warrants respectively [3] Profit Forecast and Valuation - The report forecasts a net profit growth rate of 14%, 8%, and 9% for 2026, 2027, and 2028 respectively, with a corresponding PE ratio of 26, 24, and 22 times [4] - The expected revenue growth rates for the same period are 11%, 7%, and 8% [8]

Investment Rating - The report assigns a "Buy" rating to the company, with a current price of HKD 8.83 and a fair value of HKD 9.87 [6]. Core Insights - The company reported significant growth in its FY26 interim results, achieving revenue of RMB 37.221 billion, a year-on-year increase of 11.2%, and a net profit of RMB 1.967 billion, up 318.8% year-on-year, demonstrating strong operational resilience amid industry fluctuations [6][7]. - The total sales volume for FY26H1 increased by 8.3% to 12.4 million tons, marking the highest level in three years. Revenue from various product segments, including packaging paper, cultural paper, high-end specialty paper, and sales of pulp products, showed varied growth rates [6][7]. - The company is expanding its production capacity, with a total designed annual production capacity of 31.5 million tons for paper and pulp products, and is actively pursuing expansion projects across multiple provinces [6][7]. Financial Forecasts - The company is expected to see a significant increase in revenue and net profit over the next few years, with projected revenues of RMB 71.315 billion, RMB 74.147 billion, and RMB 76.689 billion for FY26, FY27, and FY28, respectively, reflecting growth rates of 12.8%, 4.0%, and 3.4% [10][11]. - The forecasted EPS for FY26, FY27, and FY28 is RMB 0.87, RMB 0.98, and RMB 1.04, respectively, with a corresponding P/E ratio of 9.0, 8.0, and 7.5 [10][11]. - The company's gross margin is expected to improve, reaching 14.5%, 14.7%, and 14.8% in FY26, FY27, and FY28, respectively, driven by cost optimization and an increase in high-margin product offerings [9][10]. Business Segmentation - The primary business segment is packaging paper, which accounted for 90.0% of revenue in FY25, with expected growth rates of 7.7%, 3.7%, and 3.0% for FY26, FY27, and FY28 [10][11]. - The second major segment is eco-friendly cultural paper, which represented 8.6% of revenue in FY25, with projected growth rates of 64.8%, 4.0%, and 4.0% for FY26, FY27, and FY28 [8][11]. - Specialty paper and pulp businesses contribute smaller revenue shares, with expected growth driven by price recovery and new production capacity [8][11].